Abstract
The Modified Vaccinia Ankara vaccine developed by Bavarian Nordic (MVA-BN) was widely deployed to prevent Mpox during the 2022 global outbreak. This vaccine was initially approved for Mpox based on its reported immunogenicity and effectiveness in animal models, rather than evidence of clinical efficacy. However no validated correlate of protection after vaccination has been identified. Here we performed a systematic search and meta-analysis of the available data to test whether vaccinia-binding ELISA endpoint titer is predictive of vaccine effectiveness against Mpox. We observe a significant correlation between vaccine effectiveness and vaccinia-binding antibody titers, consistent with the existing assumption that antibody levels may be a correlate of protection. Combining this data with analysis of antibody kinetics after vaccination, we predict the durability of protection after vaccination and the impact of dose spacing. Although further work is required to validate this correlate, this study provides the first evidence-based approach for using antibody measurements to predict the effectiveness of Mpox vaccination.
Mpox virus (formerly Monkeypox) is a zoonotic virus endemic in West Africa, with significant outbreaks in 1980-1986 and in 1997-19981, resulting in over 20,000 total recorded cases. Prior to 2017, these outbreaks were typically small and initiated by zoonotic transmission followed by self-terminating human-to-human chains of transmission2. However, since 2017, there has been a resurgence of Mpox in Nigeria, Democratic Republic of the Congo (DRC) and other parts of Africa, attributed to waning immunity from smallpox vaccines and accumulation of cohorts that have never been vaccinated against smallpox3. In 2022, a global outbreak of Mpox resulted in 91000+ confirmed cases in 115 countries and established chains of human-human transmission leading to a renewed focus on vaccination as a preventative measure for Mpox4.
Although there is no Mpox-specific vaccine, first generation smallpox vaccination was observed to protect individuals against Mpox infection during the 1980-1986 Mpox outbreak in the DRC (then Zaire)5-8, with an estimated vaccine effectiveness of approximately 85%5, and this has also been observed in similar subsequent studies9-11. However, the livereplicating vaccinia vaccines (first and second-generation) have significant risks of serious vaccine adverse events12, which led to the development of the third-generation Modified Vaccinia Ankara live-attenuated (replication deficient) vaccine (MVA-BN). Prior to the 2022 Mpox outbreak, MVA-BN was approved by the FDA for use as a Smallpox and Mpox vaccine (two doses of 1 × 108 TCID via subcutaneous injection). Given the challenge of directly assessing the efficacy of this vaccine in an RCT, regulatory approval was based on demonstrated non-inferior immunogenicity profile and improved safety compared to the second-generation ACAM2000 vaccine13. In particular, comparing vaccinia neutralizing antibody titers induced by vaccination of MVA-BN and ACAM2000, it was deemed “reasonable to expect that this regimen of the vaccine is effective in smallpox vaccinia-naïve as well as in smallpox vaccine experienced individuals”13. This was supported by studies in nonhuman primates implicating antibodies directly in mediating protection against lethal Mpox challenge14.
Analysis of case data during the 2022 global outbreak indicates that the MVA-BN vaccine is effective for prevention of Mpox15-20, and affirms the decisions to use these vaccines during the outbreaks. However, important questions remain to be addressed. Firstly, how does MVA-BN effectiveness compare with the protection conferred by the live replicating smallpox vaccines, and how many doses are required? Further, is the protection from MVA-BN vaccination expected to be durable, and will further booster doses be required to confer durable protection against Mpox and protect individuals in potential future outbreaks?
Here we address these questions by aggregating the available data on the effectiveness of different vaccinia-based vaccination regimes in protection against Mpox. We compare protection from first generation smallpox vaccines with the protection conferred by one or two doses of the MVA-BN vaccine. Further, given the assumed role of antibodies, we aggregate data on vaccinia-specific ELISA endpoint titers (here after referred to as vaccinia-binding titers) after MVA-BN vaccination (which have been shown to correlate with neutralizing antibody titers to Mpox after vaccinia vaccination21), and study the relationship between antibody levels and effectiveness. Finally, we analyze the kinetics of antibody decay over time to predict the duration of protection afforded by 1, 2 or 3 doses of vaccination. This work offers a data-driven approach to support public health decision making on Mpox vaccination and boosting campaigns.
Competing Interest Statement
CRM is on the WHO SAGE Working Group on Smallpox and Monkeypox. The authors have no other competing interests to declare.
Funding Statement
This work is supported by an NHMRC program grant GNT1149990 (to MPD), Investigator grants (GNT1173931 to AEG, GNT2016907 to CRM and GNT1173027 to MPD) and an NHMRC Centre for Research Excellence BREATHE (GNT2006595). DSK is supported by a University of New South Wales fellowship. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used only openly available human data from the published clinical trials listed below: 1Breman, J. G. et al. Human monkeypox, 1970-79. Bull World Health Organ 58, 165-182 (1980). 2Fine, P. E., Jezek, Z., Grab, B. & Dixon, H. The transmission potential of monkeypox virus in human populations. Int J Epidemiol 17, 643-650 (1988). https://doi.org:10.1093/ije/17.3.643 3Jezek, Z. et al. Human monkeypox: a study of 2,510 contacts of 214 patients. J Infect Dis 154, 551-555 (1986). https://doi.org:10.1093/infdis/154.4.551 4Jezek, Z., Grab, B., Szczeniowski, M. V., Paluku, K. M. & Mutombo, M. Human monkeypox: secondary attack rates. Bull World Health Organ 66, 465-470 (1988). 5Rimoin, A. W. et al. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A 107, 16262-16267 (2010). https://doi.org:10.1073/pnas.1005769107 6Nolen, L. D. et al. Introduction of Monkeypox into a Community and Household: Risk Factors and Zoonotic Reservoirs in the Democratic Republic of the Congo. Am J Trop Med Hyg 93, 410-415 (2015). https://doi.org:10.4269/ajtmh.15-0168 7Whitehouse, E. R. et al. Clinical and Epidemiological Findings from Enhanced Monkeypox Surveillance in Tshuapa Province, Democratic Republic of the Congo During 2011-2015. J Infect Dis 223, 1870-1878 (2021). https://doi.org:10.1093/infdis/jiab133 8Wolff Sagy, Y. et al. Real-world effectiveness of a single dose of mpox vaccine in males. Nat Med 29, 748-752 (2023). https://doi.org:10.1038/s41591-023-02229-3 9Payne, A. B. et al. Incidence of Monkeypox Among Unvaccinated Persons Compared with Persons Receiving ≥1 JYNNEOS Vaccine Dose - 32 U.S. Jurisdictions, July 31-September 3, 2022. MMWR. Morbidity and Mortality Weekly Report 71, 1278-1282 (2022). https://doi.org:10.15585/mmwr.mm7140e3 10Payne, A. B. et al. Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons-43 US Jurisdictions, July 31-October 1, 2022. Mmwr-Morbidity and Mortality Weekly Report 71, 1560-1564 (2022). 11Bertran, M. et al. Effectiveness of one dose of MVA-BN smallpox vaccine against mpox in England using the case-coverage method: an observational study. Lancet Infect Dis 23, 828-835 (2023). https://doi.org:10.1016/S1473-3099(23)00057-9 12Dalton, A. F. et al. Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study - United States, August 19, 2022-March 31, 2023. MMWR. Morbidity and Mortality Weekly Report 72, 553-558 (2023). https://doi.org:10.15585/mmwr.mm7220a3 13Deputy, N. P. et al. Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United States. N Engl J Med 388, 2434-2443 (2023). https://doi.org:10.1056/NEJMoa2215201 14Rosenberg, E. S. et al. Effectiveness of JYNNEOS Vaccine Against Diagnosed Mpox Infection - New York, 2022. MMWR. Morbidity and Mortality Weekly Report 72, 559-563 (2023). https://doi.org:10.15585/mmwr.mm7220a4 15von Krempelhuber, A. et al. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine 28, 1209-1216 (2010). https://doi.org:10.1016/j.vaccine.2009.11.030 16Zitzmann-Roth, E. M. et al. Cardiac safety of Modified Vaccinia Ankara for vaccination against smallpox in a young, healthy study population. PLoS One 10, e0122653 (2015). https://doi.org:10.1371/journal.pone.0122653 17Pittman, P. R. et al. Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox. N Engl J Med 381, 1897-1908 (2019). https://doi.org:10.1056/NEJMoa1817307 18Greenberg, R. N. et al. A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis. PLoS One 10, e0138348 (2015). https://doi.org:10.1371/journal.pone.0138348 19Frey, S. E. et al. Safety and immunogenicity of IMVAMUNE(R) smallpox vaccine using different strategies for a post event scenario. Vaccine 31, 3025-3033 (2013). https://doi.org:10.1016/j.vaccine.2013.04.050 20Overton, E. T. et al. Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial. Open Forum Infect Dis 2, ofv040 (2015). https://doi.org:10.1093/ofid/ofv040 21Overton, E. T. et al. Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial. PLoS One 13, e0195897 (2018). https://doi.org:10.1371/journal.pone.0195897 22Ilchmann, H. et al. One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines. J Infect Dis 227, 1203-1213 (2023). https://doi.org:10.1093/infdis/jiac455 23Greenberg, R. N. et al. A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN(R)) in 56-80-Year-Old Subjects. PLoS One 11, e0157335 (2016). https://doi.org:10.1371/journal.pone.0157335 24Bavarian Nordic. A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN) Smallpox Vaccine in Vaccinia-naive Healthy Subjects, <https://clinicaltrials.gov/study/NCT01668537> (2020). 25Frey, S. E. et al. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naive subjects. Vaccine 33, 5225-5234 (2015). https://doi.org:10.1016/j.vaccine.2015.06.075 26Overton, E. et al. A randomized phase 3 trial to assess the immunogenicity and safety of 3 consecutively produced lots of freeze-dried MVA-BN(R) vaccine in healthy adults. Vaccine 41, 397-406 (2023). https://doi.org:10.1016/j.vaccine.2022.10.056 27Jackson, L. A. et al. Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial. Vaccine 35, 1675-1682 (2017). https://doi.org:10.1016/j.vaccine.2017.02.032
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data was extracted from reports of published clinical trials. Extracted data and codes for analysis will be made publicly available on GitHub upon publication.
